Medline Inc. MDLN
34.70
0.04
0.12%
as of 25 Sep
- Market cap
- $45.5B
- P/E
- —
Follow MDLN
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+3 more TTM periods Free account |
— | — | 0.00% | 0.00% | |
| — | 0.00% | 2.58% | 3.58% | ||
ROIC |
0.00% | 0.00% | 19.84% | 19.94% | |
Return on Tangible Assets |
— | 0.00% | 7.21% | 5.13% | |
Average Days of Receivables |
— | 0.00 | 46.78 | 44.98 | |
Free Cash Flow per Share |
0.00 | 4.18 | 2.79 | 2.69 | |
Free Cash Flow |
3,496.00 | 3,383.00 | 2,284.00 | 2,304.00 | |
Capital Expenditures |
(837.00) | (1,009.00) | (751.00) | (764.00) | |
Piotroski F-Score |
— | 0.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
0.00% | 13.00% | 8.89% | 8.94% | |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | |
Accounts Payable Turnover |
— | — | — | 0.00 | |
Inventory Turnover |
— | — | — | 0.00 | |
Average Days of Payables |
— | 0.00 | 0.00 | 18.32 | |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 81.93 | |
Tax Rate |
— | — | 0.00 | (0.02) | |
Research and Development Expense of Revenue |
— | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
— | — | 0.00% | 15.71% | |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.29% | |
Interest Coverage |
— | — | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 3.14 | 4.36 | |
Depreciation/Fixed assets |
0.00 | 0.56 | 0.39 | 0.40 | |
Capex/Depreciation |
(0.31) | (0.38) | (0.40) | (0.41) | |
Revenue per Share |
— | 0.00 | 35.00 | 34.67 | |
Operating CF per Share |
0.00 | 5.42 | 3.71 | 3.58 | |
Capex per Share |
0.00 | (1.25) | (0.92) | (0.89) | |
Capex to Sales |
0.00 | 0.00 | 0.03 | 0.03 | |
Net Profit Margin |
— | — | 3.37% | 2.37% |
Columns are period end dates